

BÖLÜM 63

GASTRİT, GASTROPATİLER VE PEPTİK ÜLSER

Bengi ÖZTÜRK¹

GASTRİT VE GASTROPATİ TANIMI

Gastrit ve gastropatiler; klinik, patolojik ve endoskopik görünümüne göre farklı şekillerde yorumlanabilirken, tanımlama sıklıkla histopatolojik özellikler temel alınarak yapılmaktadır. Gastrit tanımı, gastrik mukozal hasara bağlı olarak gelişen inflamasyonu tanımlamak için kullanılırken; gastropatiler ise çoğunlukla minimal inflamasyonla birlikte olan veya inflamasyonla ilişkisiz olan epitelyal hücre hasarı ve rejenerasyonla giden süreci ifade etmektedir.

GASTRİT VE GASTROPATİ SINIFLAMASI VE ETYOLOJİ

Gastritlerin sınıflandırması temel olarak akut ve kronik olarak iki grupta yapılmaktadır. Çoğu sınıflama sistemine göre akut ve kronik gastrit ayrımı hastalığın oluşum sürecine göre yapılırken aynı zamanda inflamatuvar

hücre infiltrasyonunun tipine göre de akut/kronik gastrit tanımlaması kullanılabilir. Akut gastritte nötrofil infiltrasyonu ile karakterize inflamasyon görülürken, kronik gastritteki inflamasyonda lenfosit dominant mononükleer hücreler, plazma hücreleri ve makrofajlar görülmektedir. Gastrit ve gastropatiler etyolojiye dayandırılarak da gruplandırılabilir.

Gastritlerin sınıflandırmasında evrensel olarak kabul görmüş standart bir sınıflandırma sistemi olmamakla birlikte en kapsamlı ve en sık kullanılan sınıflandırma sistemi Sydney klasifikasyonudur. Sydney klasifikasyon sistemi gastritlerin sınıflamasını akut ve kronik gastritler olarak yapmaktadır. Bu sınıflamayı yaparken de histolojik ve patofizyolojik özellikleri, lokalizasyonu ve etyolojik nedenleri temel almaktadır. Bu iki ana sınıflama dışında özel gastrit formları da mevcuttur. Belirli bir etyolojik zemine dayandırılmayan gastritler ve gastropatiler özel gastrit nedenleri arasında değerlendirilmektedir.

¹ Uzm. Dr., Kırıkkale Yüksek İhtisas Hastanesi, Gastroenteroloji Kliniği, drbengiozturk@gmail.com

KAYNAKLAR

- Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. *Am J Physiol*. 1994;266(4 Pt 1):Gv657-64.
- Annibale B, Lahner E, Fave GD. Diagnosis and management of pernicious anemia. *Curr Gastroenterol Rep*. 2011;13(6):518-24.
- Appelman HD. Gastritis: terminology, etiology, and clinicopathological correlations: another biased view. *Hum Pathol*. 1994;25(10):1006-19.
- Arents NL, Thijs JC, van Zwet AA, Kleibeuker JH. Does the declining prevalence of *Helicobacter pylori* unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. *Eur J Gastroenterol Hepatol*. 2004;16(8):779-83.
- Arents NL, van Zwet AA, Thijs JC, de Jong A, Pool MO, Kleibeuker JH. The accuracy of the *Helicobacter pylori* stool antigen test in diagnosing *H. pylori* in treated and untreated patients. *Eur J Gastroenterol Hepatol*. 2001;13(4):383-6.
- Brown TH, Davidson PF, Larson GM. Acute gastritis occurring within 24 hours of severe head injury. *Gastrointest Endosc*. 1989;35(1):37-40.
- Burdick JS, Chung E, Tanner G, Sun M, Paciga JE, Cheng JQ, et al. Treatment of Menetrier's disease with a monoclonal antibody against the epidermal growth factor receptor. *N Engl J Med*. 2000;343(23):1697-701.
- Caldwell JM, Collins MH, Stucke EM, Putnam PE, Franciosi JP, Kushner JP, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. *J Allergy Clin Immunol*. 2014;134(5):1114-24.
- Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. *Gastrointest Endosc*. 2010;71(7):1150-8.
- Carpenter HA, Talley NJ. Gastrosocopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. *Gastroenterology*. 1995;108(3):917-24.
- Casey KM, Quigley TM, Kozarek RA, Raker EJ. Lethal nature of ischemic gastropathy. *Am J Surg*. 1993;165(5):646-9.
- Chen ZM, Shah R, Zuckerman GR, Wang HL. Epstein-Barr virus gastritis: an underrecognized form of severe gastritis simulating gastric lymphoma. *Am J Surg Pathol*. 2007;31(9):1446-51.
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. *Am J Gastroenterol*. 2017;112(2):212-39.
- Coati I, Fassan M, Farinati F, Graham DY, Genta RM, Rugge M. Autoimmune gastritis: Pathologist's viewpoint. *World J Gastroenterol*. 2015;21(42):12179-89.
- Collins K, Rezuze WN. Lymphocytic gastritis in a patient with dyspepsia. *Clin Case Rep*. 2019;7(9):1791-3.
- Committee ASOP, Banerjee S, Cash BD, Dominitz JA, Baron TH, Anderson MA, et al. The role of endoscopy in the management of patients with peptic ulcer disease. *Gastrointest Endosc*. 2010;71(4):663-8.
- Correa P, Piazzuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. *Am J Gastroenterol*. 2010;105(3):493-8.
- Correa P. The biological model of gastric carcinogenesis. *IARC Sci Publ*. 2004(157):301-10.
- Culver GJ, Pirson HS, Montez M, Palanker HK. Eosinophilic gastritis. *JAMA*. 1967;200(7):641-2.
- De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide *H. pylori* antibiotic resistance: a systematic review. *J Gastrointest Liver Dis*. 2010;19(4):409-14.
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol*. 1996;20(10):1161-81.
- Dixon MF, Genta RM, Yardley JH, Correa P. Histological classification of gastritis and *Helicobacter pylori* infection: an agreement at last? The International Workshop on the Histopathology of Gastritis. *Helicobacter*. 1997;2 Suppl 1:S17-24.
- Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for *Helicobacter pylori* eradication therapy: Is superiority an illusion? *Helicobacter*. 2017;22(6).
- Ectors NL, Dixon MF, Geboes KJ, Rutgeerts PJ, Desmet VJ, Vantrappen GR. Granulomatous gastritis: a morphological and diagnostic approach. *Histopathology*. 1993;23(1):55-61.
- El-Zimaity H, Choi WT, Lauwers GY, Riddell R. The differential diagnosis of *Helicobacter pylori* negative gastritis. *Virchows Arch*. 2018;473(5):533-50.
- Esteve C, Resano A, Diaz-Tejero P, Fernandez-Benitez M. Eosinophilic gastritis due to Anisakis: a case report. *Allergol Immunopathol (Madr)*. 2000;28(1):21-3.
- Franzin G, Novelli P. Gastritis cystica profunda. *Histopathology*. 1981;5(5):535-47.
- Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, et al. Effect of proton pump inhibitors and antacid therapy on ¹³C urea breath tests and stool test for *Helicobacter pylori* infection. *Am J Gastroenterol*. 2004;99(5):823-9.
- Genta RM. Differential diagnosis of reactive gastropathy. *Semin Diagn Pathol*. 2005;22(4):273-83.
- Gjeorgievski M, Cappell MS. Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy. *World J Hepatol*. 2016;8(4):231-62.
- Goodgame RW. Gastrointestinal cytomegalovirus disease. *Ann Intern Med*. 1993;119(9):924-35.



32. Haot J, Weynand B, Jouret-Mourin A. Chronic lymphocytic gastritis. *Gut*. 1990;31(7):840
33. Hermansson M, Ekedahl A, Ranstam J, Zilling T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. *BMC Gastroenterol*. 2009;9:25
34. Hindupur S, Despotovic V. Gastric histoplasmosis. *Lancet Infect Dis*. 2006;6(1):60.
35. Hosking SW, Kennedy HJ, Seddon I, Triger DR. The role of propranolol in congestive gastropathy of portal hypertension. *Hepatology*. 1987;7(3):437-41.
36. Ivey KJ. Acute haemorrhagic gastritis: modern concepts based on pathogenesis. *Gut*. 1971;12(9):750-4.
37. Kasper P, Loeser H, Goeser T. Varioliform gastritis: an unusual endoscopic finding. *Ann Gastroenterol*. 2018;31(4):520.
38. Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of *Helicobacter pylori* infection in Japan: 2016 Revised Edition. *Helicobacter*. 2019;24(4):e12597
39. Kemp WJ, Bashir A, Dababneh H, Cohen-Gadol AA. Cushing's ulcer: Further reflections. *Asian J Neurosurg*. 2015;10(2):87-94.
40. Kim GY, Ward J, Hennessey B, Peji J, Godell C, Desta H, et al. Phlegmonous gastritis: case report and review. *Gastrointest Endosc*. 2005;61(1):168-74.
41. Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. *Medicine (Baltimore)*. 1970;49(4):299-319.
42. Lauwers GY, Fujita H, Nagata K, Shimizu M. Pathology of non-*Helicobacter pylori* gastritis: extending the histopathologic horizons. *J Gastroenterol*. 2010;45(2):131-45.
43. Lavery EA, Coyle WJ. Herpes simplex virus and the alimentary tract. *Curr Gastroenterol Rep*. 2008;10(4):417-23.
44. Leung ST, Chandan VS, Murray JA, Wu TT. Collagenous gastritis: histopathologic features and association with other gastrointestinal diseases. *Am J Surg Pathol*. 2009;33(5):788-98
45. Lichtenberger LM. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. *Biochem Pharmacol*. 2001;61(6):631-7.
46. Lin KJ, Garcia Rodriguez LA, Hernandez-Diaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? *Pharmacoepidemiol Drug Saf*. 2011;20(7):718-28.
47. Machicado J, Shroff J, Quesada A, Jelinek K, Spinn MP, Scott LD, et al. Gastritis cystica profunda: Endoscopic ultrasound findings and review of the literature. *Endosc Ultrasound*. 2014;3(2):131-4
48. Madisch A, Miehlke S, Neuber F, Morgner A, Kuhlisch E, Rappel S, et al. Healing of lymphocytic gastritis after *Helicobacter pylori* eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. *Aliment Pharmacol Ther*. 2006;23(4):473-9.
49. Maeng L, Lee A, Choi K, Kang CS, Kim KM. Granulomatous gastritis: a clinicopathologic analysis of 18 biopsy cases. *Am J Surg Pathol*. 2004;28(7):941-5.
50. Mann NS, Sachdev AJ. Acute erosive gastritis induced by aspirin, ketoprofen, ibuprofen, and naproxen: its prevention by metiamide and cimetidine. *South Med J*. 1977;70(5):562-4.
51. McCormack TT, Sims J, Eyre-Brook I, Kennedy H, Goepel J, Johnson AG, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? *Gut*. 1985;26(11):1226-32.
52. Moody FG, Cheung LY, Simons MA, Zalewsky C. Stress and the acute gastric mucosal lesion. *Am J Dig Dis*. 1976;21(2):148-54.
53. Neumann WL, Coss E, Rugge M, Genta RM. Auto-immune atrophic gastritis--pathogenesis, pathology and management. *Nat Rev Gastroenterol Hepatol*. 2013;10(9):529-41.
54. Nomura H, Miyake K, Kashiwagi S, Sugiyama T, Asaka M. A short-term eradication therapy for *Helicobacter pylori* acute gastritis. *J Gastroenterol Hepatol*. 2000;15(12):1377-81.
55. Norris JR, Haubrich WS. The incidence and clinical features of penetration in peptic ulceration. *JAMA*. 1961;178:386-9.
56. Pineton de Chambrun G, Gonzalez F, Canva JY, Gonzalez S, Houssin L, Desreumaux P, et al. Natural history of eosinophilic gastroenteritis. *Clin Gastroenterol Hepatol*. 2011;9(11):950-6 e1
57. Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in *Helicobacter pylori* diagnostics in the era of next generation sequencing. *World J Gastroenterol*. 2019;25(32):4629-60.
58. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. *Aliment Pharmacol Ther*. 2006;23(11):1587-93.
59. Pruitt BA, Jr., Foley FD, Moncrief JA. Curling's ulcer: a clinical-pathology study of 323 cases. *Ann Surg*. 1970;172(4):523-39.
60. Ricci C, Holton J, Vaira D. Diagnosis of *Helicobacter pylori*: invasive and non-invasive tests. *Best Pract Res Clin Gastroenterol*. 2007;21(2):299-313
61. Roth SH. NSAID gastropathy. A new understanding. *Arch Intern Med*. 1996;156(15):1623-8.
62. Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a tutorial. *Dig Liver Dis*. 2008;40(8):650-8.
63. Rugge M, Correa P, Dixon MF, Fiocca R, Hattori T, Lechago J, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. *Aliment Pharmacol Ther*. 2002;16(7):1249-59.
64. Rugge M, Meggio A, Pennelli G, Piscioi F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. *Gut*. 2007;56(5):631-6.

65. Rugge M, Pennelli G, Pillozzi E, Fassan M, Ingravalle G, Russo VM, et al. Gastritis: the histology report. *Dig Liver Dis.* 2011;43 Suppl 4:S373-84.
66. Sachar DB, Klein RS, Swerdlow F, Bottone E, Khilnani MT, Wayne JD, et al. Erosive syphilitic gastritis: dark-field and immunofluorescent diagnosis from biopsy specimen. *Ann Intern Med.* 1974;80(4):512-5.
67. Satoh K, Yoshino J, Akamatsu T, Itoh T, Kato M, Kamada T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. *J Gastroenterol.* 2016;51(3):177-94.
68. Scharschmidt BF. The natural history of hypertrophic gastropathy (Menetrier's disease). Report of a case with 16 year follow-up and review of 120 cases from the literature. *Am J Med.* 1977;63(4):644-52.
69. Schultz MJ, van der Hulst RW, Tytgat GN. Acute phlegmonous gastritis. *Gastrointest Endosc.* 1996;44(1):80-3.
70. Sell A, Jensen TS. Acute gastric ulcers induced by radiation. *Acta Radiol Ther Phys Biol.* 1966;4(4):289-97.
71. Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of *Helicobacter pylori* to 16 antibiotics in clinical patients. *J Clin Lab Anal.* 2018;32(4):e22339.
72. Shepherd HA, Harvey J, Jackson A, Colin-Jones DG. Recurrent retching with gastric mucosal prolapse. A proposed prolapse gastropathy syndrome. *Dig Dis Sci.* 1984;29(2):121-8.
73. Smith E, Davis J, Caldwell S. Gastric Antral Vascular Ectasia Pathogenesis and the Link to the Metabolic Syndrome. *Curr Gastroenterol Rep.* 2018;20(8):36.
74. Soreide K, Thorsen K, Harrison EM, Bingener J, Moller MH, Ohene-Yeboah M, et al. Perforated peptic ulcer. *Lancet.* 2015;386(10000):1288-98.
75. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following *Helicobacter pylori* eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. *Ann Oncol.* 2009;20(6):1086-93.
76. Sugawa C, Lucas CE, Rosenberg BF, Riddle JM, Walt AJ. Differential topography of acute erosive gastritis due to trauma or sepsis, ethanol and aspirin. *Gastrointest Endosc.* 1973;19(3):127-30.
77. Tang SJ, Daram SR, Wu R, Bhajee F. Pathogenesis, diagnosis, and management of gastric ischemia. *Clin Gastroenterol Hepatol.* 2014;12(2):246-52 e1.
78. Taylor KB. Gastritis. *N Engl J Med.* 1969;280(15):818-20.
79. Tsay FW, Hsu PI. H. pylori infection and extra-gastrointestinal diseases. *J Biomed Sci.* 2018;25(1):65.
80. Toh BH. Diagnosis and classification of autoimmune gastritis. *Autoimmun Rev.* 2014;13(4-5):459-62.
81. Tytgat GN. The Sydney System: endoscopic division. Endoscopic appearances in gastritis/duodenitis. *J Gastroenterol Hepatol.* 1991;6(3):223-34.
82. Uygur-Bayramicli O, Yavuzer D, Dolapcioglu C, Sencu S, Tuncer K. Granulomatous gastritis due to taeniasis. *J Clin Gastroenterol.* 1998;27(4):351-2.
83. Vigneri S, Termini R, Piraino A, Scialabba A, Pisciotto G, Fontana N. The stomach in liver cirrhosis. Endoscopic, morphological, and clinical correlations. *Gastroenterology.* 1991;101(2):472-8.
84. Wang AY, Peura DA. The prevalence and incidence of *Helicobacter pylori*-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. *Gastrointest Endosc Clin N Am.* 2011;21(4):613-35.
85. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. *Proc Natl Acad Sci U S A.* 1999;96(13):7563-8.
86. Washington K, Bentley RC, Green A, Olson J, Trem WR, Krigman HR. Gastric graft-versus-host disease: a blinded histologic study. *Am J Surg Pathol.* 1997;21(9):1037-46.
87. Weiland D, Dunn DH, Humphrey EW, Schwartz ML. Gastric outlet obstruction in peptic ulcer disease: an indication for surgery. *Am J Surg.* 1982;143(1):90-3.
88. Whittle BJ. Role of prostaglandins in the defense of the gastric mucosa. *Brain Res Bull.* 1980;5 Suppl 1:7-14.
89. Wig JD, Vaiphei K, Tashi M, Kochhar R. Isolated gastric tuberculosis presenting as massive hematemesis: report of a case. *Surg Today.* 2000;30(10):921-2.
90. Wolber R, Owen D, DelBuono L, Appelman H, Freeman H. Lymphocytic gastritis in patients with celiac sprue or spruelike intestinal disease. *Gastroenterology.* 1990;98(2):310-5.
91. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. *N Engl J Med.* 1987;317(19):1200-9.
92. Yamamoto T, Matsumoto J, Shiota K, Kitajima S, Goto M, Imaizumi M, et al. *Helicobacter heilmannii* associated erosive gastritis. *Intern Med.* 1999;38(3):240-3.
93. Yeaton P, Frierson HF, Jr. Octreotide reduces enteral protein losses in Menetrier's disease. *Am J Gastroenterol.* 1993;88(1):95-8.
94. Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. *Gastric Cancer.* 2018;21(4):579-87.
95. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. *Ann Surg.* 1955;142(4):709-23; discussion, 24-8.
96. Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, et al. Molecular analysis of the progression from *Helicobacter pylori*-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. *N Engl J Med.* 1998;338(12):804-10.